Last reviewed · How we verify

MaineHealth — Portfolio Competitive Intelligence Brief

MaineHealth pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Lamotrigine (drug) Lamotrigine (drug) marketed Anticonvulsant / Antiepileptic drug Voltage-gated sodium channels; glutamate release inhibition Neurology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Affiliated Hospital of Nantong University · 1 shared drug class
  2. Eisai Inc. · 1 shared drug class
  3. GlaxoSmithKline · 1 shared drug class
  4. Mario Negri Institute for Pharmacological Research · 1 shared drug class
  5. UCB Pharma · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for MaineHealth:

Cite this brief

Drug Landscape (2026). MaineHealth — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/mainehealth. Accessed 2026-05-16.

Related